Skip to main navigation Skip to search Skip to main content

Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients

  • Giuseppe Lapadula
  • , Silvia Costarelli
  • , Liliane Chatenoud
  • , Francesco Castelli
  • , Noemi Astuti
  • , Simona Di Giambenedetto
  • , Eugenia Quiros-Roldan
  • , Laura Sighinolfi
  • , Nicoletta Ladisa
  • , Massimo Di Pietro
  • , Alessia Zoncada
  • , Elisa Di Filippo
  • , Andrea Gori
  • , Paola Nasta
  • , Carlo Torti

Research output: Contribution to journalArticle

Abstract

The risk of liver enzyme elevation (LEE) after different ritonavir-boosted protease inhibitors (PI/r) has not been fully assessed in real-life settings and in populations with high rates of hepatitis C virus (HCV) coinfection.
Original languageEnglish
Pages (from-to)312-318
Number of pages7
JournalJournal of Acquired Immune Deficiency Syndromes
Volume69
DOIs
Publication statusPublished - 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Adult
  • Anti-HIV Agents
  • Cohort Studies
  • Drug Therapy, Combination
  • Female
  • HIV Infections
  • Hepatitis B
  • Hepatitis C
  • Humans
  • Italy
  • Liver
  • Male
  • Middle Aged
  • Protease Inhibitors
  • Risk Factors
  • Ritonavir

Fingerprint

Dive into the research topics of 'Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients'. Together they form a unique fingerprint.

Cite this